Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article
Special Issue

Propolis: Properties, Application, and Its Potential

View this Special Issue

Review Article | Open Access

Volume 2013 |Article ID 175135 | 8 pages | https://doi.org/10.1155/2013/175135

Emerging Roles of Propolis: Antioxidant, Cardioprotective, and Antiangiogenic Actions

Academic Editor: Vassya Bankova
Received15 Jan 2013
Revised19 Mar 2013
Accepted20 Mar 2013
Published08 Apr 2013


Propolis has attracted attention in recent years due to its beneficial effects, which make it a potential preventive and therapeutic agent as well as a useful additive in food and cosmetics. The aim of this review is to discuss the growing evidence that propolis may, via a diverse array of biological actions, assist in the prevention of some inflammation-mediated pathologies including cardiovascular disease. The active components of propolis that have been identified so far include polyphenols and flavonoids. These compounds have cardioprotective, vasoprotective, antioxidant, antiatherosclerotic, anti-inflammatory and antiangiogenic actions. Many studies have been undertaken to elucidate the mechanism(s) by which propolis acts, which involve cellular signaling targets and interactions at the genomic level. This review will highlight the effects of propolis that may assist in the prevention of chronic degenerative diseases, such as cardiovascular disease.

1. Introduction

The growing market for natural products and alternative medicines has renewed interest in bee products, such as honey, royal jelly, pollen, and propolis [1, 2]. Propolis is the generic name for a complex resinous mixture collected by honey bees from the buds and exudates of various plants. Once collected, this material is enriched with saliva and enzyme-containing secretions and used in the construction, adaptation, and protection of hives [3, 4].

In recent years, many studies of the chemistry of propolis have been published, which reveal that its highly variable composition is influenced by the local flora at the collection site [57]. Although many biological activities of propolis are consistently observed, the components responsible vary between geographic and climatic zones [7].

There is considerable evidence on various chemical and biological aspects of propolis, but the therapeutic application and utilization by the pharmaceutical industry are still limited. This is mainly due to the variability of its chemical composition with geographical origin because bees utilize different plants in different ecosystems. Identification of the major compounds in propolis samples is essential; reports of the biological properties of propolis should include a detailed investigation of its composition and botanical sources [7, 8].

The constituents of propolis include polyphenols (flavonoids, phenolic acids, and esters), terpenoids, steroids, and amino acids [9]. There has been extensive research into the composition and biological activities of propolis from various countries [1013]. Propolis samples from Europe, South America, and Asia have different compositions and therefore different biological activities [12, 14, 15]. However, propolis samples generally show great similarity in their overall composition, regardless of botanical source [15]. Brazilian red propolis has been found in two reports to contain high concentrations of phenolic compounds, 232 mg/g [16] and 257.98 mg/g, respectively [17]. Brazilian propolis also contained higher concentrations of total phenols than samples from other countries: China,  mg/g [18] and  mg/g [19]; Korea,  mg/g [20]; Argentina, 187 mg/g [21]; India,  mg/g [10]; Portugal,  mg/g [22]; Cyprus,  mg/g [23]; and Thailand,  mg/g [19].

Studies indicate that propolis from Europe and China contains many flavonoids and phenolic acids; tropical propolis generally contains low concentrations of flavonoids [21, 24, 25].

Studies of propolis demonstrate the complexity of its composition and pharmacology; some compounds act independently, while others act synergistically. The therapeutic potential of propolis and its constituents has been the subject of many studies, which have established many pharmacological actions in preclinical testing.

In particular, propolis shows therapeutic potential and may have applications in the pharmaceutical and food processing industries [2527]. Propolis reportedly has a range of biological activities, including immunomodulatory [28, 29], antibacterial [30], fungicidal [31, 32], anti-inflammatory, healing [33], analgesic/anesthetic [34, 35], and anticarcinogenic effects [36].

The relationship between oxidative stress, cardiovascular disease, and angiogenesis is well established. Events related to the pathophysiology of angiogenesis and associated cytokines and growth factors can lead to a poor prognosis in many diseases. In fact, chronic cardiovascular disease, oxidative stress, and angiogenesis are strongly associated with one another. In this review, we will present evidence that propolis extracts and their bioactive compounds have antioxidant, cardioprotective, and antiangiogenic activities (Figure 1).

2. Antioxidant Activity

It is well established that cellular metabolism generates reactive oxygen species (ROS), such as hydrogen peroxide (H2O2), the superoxide anion ( ), and the highly reactive hydroxyl ion ( ), as well as reactive nitrogen species (RNS), especially nitric oxide (NO). ROS and RNS are ideal signaling molecules because they are locally generated, are highly and rapidly diffusible, and can be neutralized by cellular antioxidants [37, 38]. ROS are usually detoxified by intracellular enzymes, such as glutathione, superoxide dismutase, and catalase [39]. However, unbalanced production and degradation of ROS and RNS can result in accumulation of these reactive species, commonly referred to as oxidative stress. Exposure of macromolecules (lipid, proteins, DNA, etc.) to reactive species results in oxidative modifications with deleterious effects [40, 41].

The antioxidant capacity of propolis may be related to some of its biological effects, including chemoprevention. The flavonoids in propolis are powerful antioxidants, capable of scavenging free radicals and thereby protecting the cell membrane against lipid peroxidation [42]. Moreover, ROS and RNS, together with other factors, are involved in cellular ageing and death in conditions, such as cardiovascular disease, arthritis, cancer, diabetes, Parkinson’s disease, and Alzheimer’s disease [4347]. Propolis can reduce cellular levels of H2O2 and NO, which may be involved in its anti-inflammatory effects [48].

Diverse compounds from propolis have been described as potent inhibitors of oxidative stress. It is well known that the composition of propolis is variable; however, one of its major components, caffeic acid phenethyl ester (CAPE), blocks ROS production in several systems [49]. CAPE has also been identified as one of the major cancer chemopreventive and anti-inflammatory compounds in propolis. In vitro, propolis inhibits peroxidation of LDL and nitration of proteins. Moreover, in bovine aortic endothelial cells, propolis was reported to increase eNOS expression and inhibit NADPH oxidase (NOX) [50]. In vivo, propolis can increase antioxidant capacity in animals [51] and humans [52], leading to decreased lipid peroxidation, which is strongly associated with the risk of cardiovascular disease [53, 54]. Turkish propolis inhibited hydrogen peroxide (H2O2-) induced damage to DNA in cultured fibroblasts [55]. The antioxidant activity of phenolic components of the Turkish propolis may reduce damage to DNA induced by H2O2, which may be related to its chemopreventive activity. Red propolis from Cuba has shown protective effects in models of alcohol-induced liver damage, most likely due to its antioxidant properties [56]. Propolis inhibited macrophage apoptosis via effects on glutathione (GSH) and the tumor necrosis factors/nuclear factor kappa B (TNF/NF-κB) pathway [57, 58]. Moreover, Brazilian propolis from Baccharis dracunculifolia modulated 1,2-dimethlyhydrazine (DMH-) induced DNA damage in colon cells [59].

Isla et al. [60] described the protective effect of the Argentinian propolis from different sources against copper-mediated oxidative modification of lipids in unfractionated serum. Five types of Argentinian propolis, collected in different regions, inhibited lipid oxidation during the initiation and propagation phases. All five types of propolis diminished the maximal rate and extent of diene production, indicating that flavonoids can scavenge free radicals, such as superoxide [61, 62], protecting serum lipids from oxidation [60]. Jasprica et al. [52] showed that daily intake of powdered propolis for 15 days decreased the plasma malondialdehyde concentration in men. The extract (0.65 g), available in Croatian community pharmacies, contained 2.5% total flavonoids, equivalent to 16.25 mg of galangin. After 30 days of treatment, an increase in superoxide dismutase activity and changes in red blood cell parameters were detected, including cell count, hemoglobin and mean corpuscular volume, and cell distribution.

The antioxidant effect of Brazilian red propolis has been attributed to chalcones and isoflavonoids (including 7-O-methylvestitol, medicarpin, and 3,4,2′,3′-tetrahydrochalcone) that act as electron donors [63]. Furthermore, total flavonoid content in Brazilian red propolis is correlated with antioxidant activity, suggesting that all the phenolic and flavonoid compounds present contribute to this activity [64]. Chinese red propolis had a higher antioxidant activity than propolis from other sources, which was attributed predominantly to CAPE [65]. Chilean propolis also has antioxidant properties, which are correlated with its chemical composition [66]. Additionally, the antioxidant and free-radical-scavenging properties of propolis may be due to its phenylpropanoid content [67]. Thus, the available data indicate that propolis of different origins and distinct compositions consistently exhibit antioxidant actions. In addition to this antioxidant effect, bioactive compounds in propolis influence a large number of biochemical signaling pathways, and therefore physiological and pathological processes. Antioxidant capacity is one of the most important properties of propolis. Although there are several studies corroborating the potential antioxidant activity of propolis, there is no robust data on the safe dose in humans. Thus, there is need for clinical studies using propolis and its biologically active compounds, including studies of safety and bioavailability.

3. Cardioprotective Activity

The modulation of cardiovascular disease markers by propolis has been shown in several studies. In vitro and in vivo assays have been developed to elucidate the molecular mechanisms of this beneficial effect: regulation of glucose and lipoprotein metabolism; modulation of gene expression; decrease of the activity of scavenger receptors, inflammatory cytokines, and oxidative stress; improvement of endothelial function; and inhibition of platelet aggregation.

Atherosclerosis is a complex process involving the accumulation and modification of plasma lipoproteins in the arterial wall as well as the recruitment and proliferation of immune cells. This process advances through a series of stages beginning with the appearance of a fatty streak lesion, composed largely of foam cells, which are lipid-engulfed macrophages. The fatty streak evolves into a complex atherosclerotic plaque consisting of a lipid core covered by a fibrous cap, with some areas that are rich in inflammatory cells [6870]. Several authors have postulated that dietary polyphenols reduce the risk of cardiovascular disorders and prevent the development of atheromatous plaques [7173]. Thus, as a rich source of polyphenols, propolis represents a potential alternative strategy for the prevention of cardiovascular disorders.

Propolis has been shown to modulate lipid and lipoprotein metabolism. Propolis administration diminished liver cholesterol and triglyceride content and decreased the rate of hepatic triglyceride synthesis in rats [74, 75]. In LDL receptor knockout mice (LDLr−/−), treatment with Brazilian red propolis (250 mg/kg/day) decreased levels of triacylglycerol (TAG), total cholesterol (TC), and non-high-density lipoprotein cholesterol (non-HDL-C) [76]. LDLr−/− mice treated with Brazilian green propolis, which is rich in Artepillin C, pinocembrin, kaempferol, or with Chilean brown propolis, which is rich in pinocembrin, CAPE, quercetin, and galangin, also presented low levels of non-HDL-C. Moreover, mice treated with Brazilian red propolis showed significantly reduced TAG and TC, and increased HDL-C, compared to untreated mice. Furthermore, Turkish propolis, which is rich in flavonoids (mainly galangin, quercetin, kaempferol, apigenin, pinobanksin, pinocembrin, and pinostrobin) prevented alcohol-induced acute liver damage and lipid accumulation and induced beneficial changes in the serum lipid profile. HDL levels were high, and LDL levels were low, in mice treated with propolis and alcohol compared to alcohol only [59]. Moreover, propolis also positively affected HDL and LDL levels in rats. Treatment of diabetic rats with propolis of poplar origin diminished levels of total cholesterol, LDL-cholesterol, VLDL-cholesterol, and triglycerides, reinforcing the case that propolis modulates lipid metabolism and may be helpful in syndromes caused by blood lipid abnormalities [75].

In a recent study, the authors hypothesized that propolis may aid in the prevention rather than treatment of atherosclerosis. LDLr−/− mice were treated with distinct polyphenol-rich propolis extracts (250 mg polyphenols/mL/Kg) [76]. Brazilian green, Brazilian red, and Chilean brown propolis reduced the area of atherosclerotic lesions when administered preventively. The strongest inhibitory effect was observed for Brazilian red propolis, which also induced regression of atherosclerotic lesions [76]. Polyphenols from propolis inhibited the progression of atherosclerosis in LDLr−/− mice by improving the lipid profile and by downregulating proinflammatory cytokines, chemokines, and angiogenic factors. Propolis downregulated the mRNA expression of key genes involved in the atherosclerotic process, such as MCP-1, INFg, IL6, CD36, and TGFβ [76].

It is well known that the modification of the lipid profile is strongly associated with cardiovascular disease [76, 77]. Propolis diminished total cholesterol and elevated HDL-cholesterol in mice. One proposed mechanism of the hypocholesterolemic action of propolis involves the ABCA1 receptor. Many types of propolis upregulate ABCA1 gene expression, which is associated with increased HDL levels; thus, ABCA1 up-regulation may be one mechanism by which propolis improves the lipid profile [76].

An ethanolic extract of Brazilian red propolis (EERP) enhanced ABCA1 promoter activity in THP-1 macrophages [77]. Additionally, cholesterol efflux from macrophages to ApoA-I was significantly increased in a dose-dependent manner by EERP treatment. Thus, EERP significantly enhanced ApoA-I-mediated cholesterol efflux in THP-1 macrophages, which was accompanied by a marked up-regulation of the ABCA1 gene. The effect of EERP on ABCA1-dependent cholesterol efflux may be due to the activation of PPARγ and LXRα [77]. In HepG2 and Raw 264.7 cell lines, EEP promoted cholesterol efflux and increased the expression of ABCA1 and ABCG1. Accordingly, C57BL/6 mice treated with 50 mg/kg EEP once a day for 4 weeks by oral gavage showed increased plasma HDL-cholesterol but unchanged LDL-cholesterol [78]. Thus, in vitro and in vivo data suggest that the beneficial effects of propolis on lipid profile may be one of the mechanisms involved in its atheroprotective effects. This finding suggests that polyphenols from propolis may be useful for the prevention of atherosclerosis.

Platelet aggregation is a major contributor to the atherosclerotic process. Propolis components have shown important effects on platelet aggregation. CAPE (15 and 25 μM) markedly inhibited collagen-stimulated platelet aggregation. As CAPE is involved in various inhibitory pathways influencing platelet aggregation, it may be an important contributor to the potent antiplatelet actions of propolis [79].

NO is an important vasoactive mediator, with vasodilatory and antiaggregative actions that protect blood vessels when released from endothelial cells at low concentrations. However, when NO is produced in high concentrations by inflammatory cells, it may react with other nitrogen and oxygen species, inducing oxidative and/or nitrosative stress. Following the treatment of diabetic mice with poplar propolis, the levels of NO and nitric oxide synthase (NOS) decreased compared to nondiabetic mice [75]. Propolis decreases NO level by decreasing NOS activity, thus protecting blood vessel endothelial cells and reducing neuronal toxicity. Additionally, propolis exerts pharmacological effects by decreasing the actions of NO and PGE2 as well as by reducing the activation of protein kinase in diabetes [75, 80]. Moreover, ethanolic extracts of propolis (EEP) inhibit NO production by decreasing iNOS expression in Raw 264.7 macrophages and by directly inhibiting the catalytic activity of iNOS. The inhibitory effect of EEP on LPS plus IFN-g-induced NO production is mediated either by inhibition of iNOS gene transcription via an action on NF-κB sites in the iNOS promoter or by direct inhibition of the catalytic activity of iNOS [81]. As excess NO production has been implicated in the cardiovascular inflammatory process, the anti-inflammatory activities of EEP may also be mediated by modulation of NO levels.

It is well established that proliferation of vascular smooth muscle cells (VSMCs) is involved in the onset of atherosclerosis. Roos et al. [82] evaluated the antiproliferative activity of CAFE, one of the major components of propolis and honey-derived products, in primary rat aortic VSMCs stimulated by platelet-derived growth factor (PDGF). CAFE inhibited proliferation of VSMCs upon exposure to PDGF in a dose-dependent manner, by interfering with cell cycle progression from the G0/1- to the S-phase. This study indicates that the inhibition of smooth muscle cell proliferation may also be involved in the atheroprotective action of propolis.

4. Antiangiogenic Activity

Angiogenesis is the multistep process by which blood vessels are formed. This tightly regulated process involves the migration, proliferation, and differentiation of endothelial cells [83]. Regulation of angiogenesis is absent or aberrant in several diseases characterized by persistent, inappropriate blood vessel development. Inappropriate angiogenesis occurs in more than 80 diseases, particularly in many types of cancer and inflammatory diseases as atherosclerosis [84, 85].

According to Keshavarz et al. [86], green propolis extracts containing artepillin C and CAPE significantly reduced the number of new vessels formed and the expression of metalloproteinases (MMPs) and production of vascular endothelial growth factor (VEGF) from endothelial cells [87]. Different steps of angiogenesis can be affected by propolis and its components. Brazilian propolis and its major component, artepillin C, can inhibit proliferation of human umbilical vein endothelial cells (HUVEC), as well as endothelial cell migration and capillary tube formation, in a dose-dependent manner. Moreover, artepillin C can suppress angiogenesis in both in vivo and in vitro models, while CAPE inhibits MMP-2, MMP-9, and VEGF activity [8790].

The effects of Brazilian propolis on HUVEC apoptosis were investigated by Xuan et al. [91]. At a low concentration (12.5 μg/mL), the polyphenols in ethanol extracts of Brazilian propolis decreased the expression of integrin b4 and p53 and the production of ROS. The opposite effects were observed at high polyphenol concentrations (25 and 50 μg/mL), along with depression of mitochondrial membrane potential. Thus, high doses of polyphenols from Brazilian propolis may induce HUVEC apoptosis by acting on the integrin b4 and p53 signaling pathway, resulting in disturbance of mitochondrial membrane potential and increased ROS generation.

Daleprane et al. [92] investigated the actions of polyphenols from Brazilian red propolis on models of angiogenesis. Brazilian red propolis is rich in 1,2,3-trimethoxy-5-(2-propenyl)-benzene, methoxyeugenol, homopterocarpin, medicarpin, 2,4,6-trimethylphenol, 49,7-dimethoxy-29-isoflavonol, 7,49-dihydroxyisoflavone, and 2H-1-benzopyran-7-ol [64]. Brazilian red propolis (10 mg/L) reduced the migration and sprouting of endothelial cells, attenuated the formation of new blood vessels, and decreased the differentiation of embryonic stem cells into CD31-positive cells. Moreover, Brazilian red propolis inhibited hypoxia- or dimethyloxalylglycine-induced mRNA and protein expression of the crucial angiogenesis promoter, vascular endothelial growth factor (VEGF), in a time-dependent manner [92].

Hypoxia is implicated in many inflammatory diseases. The proposal that hypoxia can induce inflammation has gained general acceptance from studies of the hypoxia signaling pathway [93]. Brazilian red propolis decreases accumulation of hypoxia-inducible factor 1 alpha (HIF1α) under hypoxic conditions, which in turn attenuates VEGF gene expression [92]. Reduced HIF1α protein half-life was associated with increased von Hippel-Lindau (pVHL-) dependent proteasomal degradation of HIF1α and reduced Cdc42 protein expression [92].

Brazilian green propolis extract, which is rich in artepillin C, was evaluated by Hattori et al. for its effects on cellular responses to hypoxia [94]. Five compounds that modulated HIF-1 activity were identified. Hydroxycinnamic acid derivatives from Brazilian green propolis inhibited not only HIF-1 transcriptional activity but also hypoxia-induced expression of HIF-1α protein and downstream target genes, such as Glucose transporter 1, Hexokinase 2, and vascular endothelial growth factor A. Furthermore, the HIF-1 inhibitors also inhibited angiogenesis. Daleprane et al. [76] investigated the effect of polyphenols from Brazilian propolis on angiogenic gene expression in atherosclerotic lesions of LDLr−/− mice, finding that angiopoietin I, angiopoietin II, VEGF, fibroblast growth factor, metalloproteinases 2 and 9, platelet-derived growth factor, and platelet endothelial cell adhesion molecule were downregulated by polyphenols from Brazilian red and green propolis.

It has been reported that the propolis extracts show antiproliferative activity and that both extracts induced cell death by necrosis [95]. The latter result indicates that certain compounds contained in propolis possess cytocidal activity based on necrosis rather than apoptosis. On the other hand, polyphenols, which are tumor necrosis factor-related, apoptosis inducing ligands, preferentially induce apoptosis in cancer cells and are not toxic to normal cells [96]. These results are therefore not consistent with each other. The inconsistency of propolis activity may be due to the presence of numerous compounds in varying levels, depending on their geographical origin. Generally, biological activity has been assessed by independent groups, making a direct comparison of their work difficult. Propolis-based medicines are often prepared from ethanol extracts of honey hive, as the extracts are generally water insoluble. Further studies are required to establish the quantity and safety control criteria for propolis to allow it to be used safely, and to gain the maximum benefit from its biological activities.

In vitro and in vivo studies are uncovering antiangiogenic activity in many natural health products, including propolis extracts and their constituents. Further preclinical research is required to determine whether individual compounds or complex mixtures will be optimal for clinical trials. A potential advantage of phytochemicals and other compounds from propolis is that they may act through multiple cellular signaling pathways, acting in different pathophysiological conditions, while also inhibiting angiogenesis and reducing inflammation. Overall, propolis constituents may be helpful as auxiliary therapies for diseases in which angiogenesis must be controlled, such as cancer and cardiovascular disease.

5. Perspectives on Propolis Utilization

Propolis contains a broad spectrum of compounds that have many biological activities. It is considered a useful product and is already used in alternative medicine. Recently, there has been a growing interest in its utilization by the food processing, cosmetic, and pharmaceutical industries. Considering this, further studies on the bioactive constituents of propolis are necessary to identify interactions mediating their biological effects. Further studies are also required on their bioavailability, stability in different preparations, and safe and effective doses for prevention or treatment of disease in animals and humans.

Conflict of Interests

The authors declare no conflict of interests.


  1. I. Hyodo, N. Amano, K. Eguchi et al., “Nationwide survey on complementary and alternative medicine in cancer patients in Japan,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2645–2654, 2005. View at: Publisher Site | Google Scholar
  2. S. P. Myers and P. A. Cheras, “The other side of the coin: safety of complementary and alternative medicine,” Medical Journal of Australia, vol. 181, no. 4, pp. 222–225, 2004. View at: Google Scholar
  3. M. C. Búfalo, J. M. G. Candeias, and J. M. Sforcin, “In Vitro Cytotoxic Effect of Brazilian Green Propolis on Human Laryngeal Epidermoid Carcinoma (HEp-2) Cells,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 4, pp. 483–487, 2009. View at: Publisher Site | Google Scholar
  4. S. Castaldo and F. Capasso, “Propolis, an old remedy used in modern medicine,” Fitoterapia, vol. 73, supplement 1, pp. S1–S6, 2002. View at: Google Scholar
  5. A. Russo, R. Longo, and A. Vanella, “Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin,” Fitoterapia, vol. 73, supplement 1, pp. S21–S29, 2002. View at: Publisher Site | Google Scholar
  6. G. A. Burdock, “Review of the biological properties and toxicity of bee propolis,” Food and Chemical Toxicology, vol. 36, no. 4, pp. 347–363, 1998. View at: Publisher Site | Google Scholar
  7. J. M. Sforcin and V. Bankova, “Propolis: is there a potential for the development of new drugs?” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 253–260, 2011. View at: Publisher Site | Google Scholar
  8. V. Bankova, “Chemical diversity of propolis and the problem of standardization,” Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 114–117, 2005. View at: Publisher Site | Google Scholar
  9. W. Zhu, M. Chen, Q. Shou, Y. Li, and F. Hu, “Biological activities of Chinese propolis and Brazilian propolis on streptozotocin-induced type 1 diabetes mellitus in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 468529, 8 pages, 2011. View at: Publisher Site | Google Scholar
  10. R. A. Laskar, I. Sk, N. Roy, and N. A. Begum, “Antioxidant activity of Indian propolis and its chemical constituents,” Food Chemistry, vol. 122, no. 1, pp. 233–237, 2010. View at: Publisher Site | Google Scholar
  11. L. L. Chaillou and M. A. Nazareno, “Bioactivity of propolis from Santiago del Estero, Argentina, related to their chemical composition,” LWT—Food Science and Technology, vol. 42, no. 8, pp. 1422–1427, 2009. View at: Publisher Site | Google Scholar
  12. M. Hernandez, O. Cuesta-Rubio, M. C. Fernandez et al., “Studies on the constituints of yellow Cuban própolis: CG-MS determination of triterpenoids and flavonoids,” Journal of Agricultural and Food Chemistry, vol. 58, pp. 4725–4730, 2010. View at: Google Scholar
  13. T. L. C. Oldoni, I. C. R. Cabral, M. A. B. R. D’Arcea et al., “Isolation and analysis of bioactive isoflavonoids and chalcone from a new type of Brazilian propolis,” Separation and Purification Technology, vol. 77, pp. 208–213, 2011. View at: Google Scholar
  14. M. G. Miguel, S. Nunes, S. A. Dandlen, A. M. Cavaco, and M. D. Antunes, “Phenols and antioxidant activity of hydro-alcoholic extracts of propolis from Algarve, South of Portugal,” Food and Chemical Toxicology, vol. 48, no. 12, pp. 3418–3423, 2010. View at: Publisher Site | Google Scholar
  15. M. R. Ahn, S. Kumazawa, T. Hamasaka, K. S. Bang, and T. Nakayama, “Antioxidant activity and constituents of propolis collected in various areas of Korea,” Journal of Agricultural and Food Chemistry, vol. 52, no. 24, pp. 7286–7292, 2004. View at: Publisher Site | Google Scholar
  16. S. M. Alencar, T. L. C. Oldoni, M. L. Castro et al., “Chemical composition and biological activity of a new type of Brazilian propolis: red propolis,” Journal of Ethnopharmacology, vol. 113, no. 2, pp. 278–283, 2007. View at: Publisher Site | Google Scholar
  17. I. S. R. Cabral, T. L. C. Oldoni, A. Prado et al., “Phenolic composition, antibacterial and antioxidant activities of Brazilian red propolis,” Química Nova, vol. 32, no. 6, pp. 1523–1527, 2009. View at: Google Scholar
  18. M. R. Ahn, S. Kumazawa, Y. Usui et al., “Antioxidant activity and constituents of propolis collected in various areas of China,” Food Chemistry, vol. 101, no. 4, pp. 1383–1392, 2007. View at: Publisher Site | Google Scholar
  19. S. Kumazawa, H. Goto, T. Hamasaka, S. Fukumoto, T. Fujimoto, and T. Nakayama, “A new prenylated flavonoid from propolis collected in Okinawa, Japan,” Bioscience, Biotechnology and Biochemistry, vol. 68, no. 1, pp. 260–262, 2004. View at: Publisher Site | Google Scholar
  20. Y. M. Choi, D. O. Noh, S. Y. Cho, H. J. Suh, K. M. Kim, and J. M. Kim, “Antioxidant and antimicrobial activities of propolis from several regions of Korea,” LWT—Food Science and Technology, vol. 39, no. 7, pp. 756–761, 2006. View at: Publisher Site | Google Scholar
  21. V. S. Bankova, S. L. de Castro, and M. C. Marcucci, “Propolis: recent advances in chemistry and plant origin,” Apidologie, vol. 31, no. 1, pp. 3–15, 2000. View at: Google Scholar
  22. L. Moreira, L. G. Dias, J. A. Pereira, and L. Estevinho, “Antioxidant properties, total phenols and pollen analysis of propolis samples from Portugal,” Food and Chemical Toxicology, vol. 46, no. 11, pp. 3482–3485, 2008. View at: Publisher Site | Google Scholar
  23. N. Kalogeropoulos, S. J. Konteles, E. Troullidou, I. Mourtzinos, and V. T. Karathanos, “Chemical composition, antioxidant activity and antimicrobial properties of propolis extracts from Greece and Cyprus,” Food Chemistry, vol. 116, no. 2, pp. 452–461, 2009. View at: Publisher Site | Google Scholar
  24. M. L. Castro, A. M. D. Nascimento, M. Ikegaki, C. M. Costa-Neto, S. M. Alencar, and P. L. Rosalen, “Identification of a bioactive compound isolated from Brazilian propolis type 6,” Bioorganic and Medicinal Chemistry, vol. 17, no. 14, pp. 5332–5335, 2009. View at: Publisher Site | Google Scholar
  25. K. Salomão, P. R. S. Pereira, L. C. Campos et al., “Brazilian propolis: correlation between chemical composition and antimicrobial activity,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 317–324, 2008. View at: Publisher Site | Google Scholar
  26. P. L. Miorin, N. C. Levy, A. R. Custodio, W. A. Bretz, and M. C. Marcucci, “Antibacterial activity of honey and propolis from Apis mellifera and Tetragonisca angustula against Staphylococcus aureus,” Journal of Applied Microbiology, vol. 95, no. 5, pp. 913–920, 2003. View at: Publisher Site | Google Scholar
  27. J. M. Murad, S. A. Calvi, A. M. V. C. Soares, V. Bankova, and J. M. Sforcin, “Effects of propolis from Brazil and Bulgaria on fungicidal activity of macrophages against Paracoccidioides brasiliensis,” Journal of Ethnopharmacology, vol. 79, no. 3, pp. 331–334, 2002. View at: Google Scholar
  28. C. L. Orsatti, F. Missima, A. C. Pagliarone et al., “Propolis immunomodulatory action in vivo on toll-like receptors 2 and 4 expression and on pro-inflammatory cytokines production in mice,” Phytotherapy Research, vol. 24, no. 8, pp. 1141–1146, 2010. View at: Publisher Site | Google Scholar
  29. F. Missima and J. M. Sforcin, “Green Brazilian propolis action on macrophages and lymphoid organs of chronically stressed mice,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 1, pp. 71–75, 2008. View at: Publisher Site | Google Scholar
  30. G. Z. Gonsales, R. O. Orsi, A. Fernandes Jr., P. Rodrigues, and S. R. C. Funari, “Antibacterial activity of propolis collected in different regions of Brazil,” Journal of Venomous Animals and Toxins Including Tropical Diseases, vol. 12, no. 2, pp. 276–284, 2006. View at: Publisher Site | Google Scholar
  31. S. Silici, N. A. Koç, D. Ayangil, and S. Çankaya, “Antifungal activities of propolis collected by different races of honeybees against yeasts isolated from patients with superficial mycoses,” Journal of Pharmacological Sciences, vol. 99, no. 1, pp. 39–44, 2005. View at: Publisher Site | Google Scholar
  32. K. F. D. Dota, M. E. L. Consolaro, T. I. E. Svidzinski, and M. L. Bruschi, “Antifungal activity of brazilian propolis microparticles against yeasts isolated from vulvovaginal candidiasis,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 201953, 8 pages, 2011. View at: Publisher Site | Google Scholar
  33. L. T. Moraes, P. C. Trevilatto, A. M. T. Grégio, M. A. N. Machado, and A. A. S. Lima, “Quantitative analysis of mature and immature collagens during oral wound healing in rats treated by Brazilian propolis,” Journal of International Dental and Medical Research, vol. 4, no. 3, pp. 106–110, 2011. View at: Google Scholar
  34. N. I. Silvestre, G. M. Stranieri, and P. M. Bazerqu, “Anesthesia (Sollman modified test) of propolis compared with lidocaine,” Journal of Dental Research, vol. 64, no. 4, p. 640, 1985. View at: Google Scholar
  35. N. Paulino, C. Teixeira, R. Martins et al., “Evaluation of the analgesic and anti-inflammatory effects of a Brazilian green propolis,” Planta Medica, vol. 72, no. 10, pp. 899–906, 2006. View at: Publisher Site | Google Scholar
  36. D. P. D. S. Leitão, A. A. da Silva Filho, A. C. M. Polizello, J. K. Bastos, and A. C. C. Spadaro, “Comparative evaluation of in-vitro effects of Brazilian green propolis and Baccharis dracunculifolia extracts on cariogenic factors of Streptococcus mutans,” Biological and Pharmaceutical Bulletin, vol. 27, no. 11, pp. 1834–1839, 2004. View at: Publisher Site | Google Scholar
  37. D. Metodiewa and C. Kośka, “Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview,” Neurotoxicity Research, vol. 1, no. 3, pp. 197–233, 2000. View at: Google Scholar
  38. S. K. Powers, E. E. Talbert, and P. J. Adhihetty, “Reactive oxygen and nitrogen species as intracellular signals in skeletal muscle,” Journal of Physiology, vol. 589, no. 9, pp. 2129–2138, 2011. View at: Publisher Site | Google Scholar
  39. J. M. van Raamsdonk and S. Hekimi, “Reactive oxygen species and aging in Caenorhabditis elegans: causal or casual relationship?” Antioxidants and Redox Signaling, vol. 13, no. 12, pp. 1911–1953, 2010. View at: Publisher Site | Google Scholar
  40. M. S. Cooke, M. D. Evans, M. Dizdaroglu, and J. Lunec, “Oxidative DNA damage: mechanisms, mutation, and disease,” FASEB Journal, vol. 17, no. 10, pp. 1195–1214, 2003. View at: Publisher Site | Google Scholar
  41. L. Fialkow, Y. Wang, and G. P. Downey, “Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function,” Free Radical Biology and Medicine, vol. 42, no. 2, pp. 153–164, 2007. View at: Publisher Site | Google Scholar
  42. D. Kolankaya, G. Selmanoǧlu, K. Sorkun, and B. Salih, “Protective effects of Turkish propolis on alcohol-induced serum lipid changes and liver injury in male rats,” Food Chemistry, vol. 78, no. 2, pp. 213–217, 2002. View at: Publisher Site | Google Scholar
  43. V. Di Matteo and E. Espósito, “Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis,” CNS & Neurological Disorders—Drug Targets, vol. 2, no. 2, pp. 95–107, 2003. View at: Google Scholar
  44. S. A. Lipton, Z. Gu, and T. Nakamura, “Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders,” International Review of Neurobiology, vol. 82, pp. 1–27, 2007. View at: Publisher Site | Google Scholar
  45. K. T. Kishida and E. Klann, “Sources and targets of reactive oxygen species in synaptic plasticity and memory,” Antioxidants and Redox Signaling, vol. 9, no. 2, pp. 233–244, 2007. View at: Publisher Site | Google Scholar
  46. J. T. Keeney, A, M. Swomley, S. Förster, J. L. Harris, R. Sultana, and D. A. Butterfield, “Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration,” Proteomics Clinical Applications, vol. 7, no. 1-2, pp. 109–122, 2013. View at: Publisher Site | Google Scholar
  47. D. A. Butterfield and I. Dalle-Donne, “Redox proteomics,” Antioxidants & Redox Signaling, vol. 17, no. 11, pp. 1487–1489, 2012. View at: Google Scholar
  48. K. Tan-No, T. Nakajima, T. Shoji et al., “Anti-inflammatory effect of propolis through inhibition of nitric oxide production on carrageenin-induced mouse paw edema,” Biological and Pharmaceutical Bulletin, vol. 29, no. 1, pp. 96–99, 2006. View at: Publisher Site | Google Scholar
  49. M. Hoşnuter, A. Gürel, O. Babucçu, F. Armutcu, E. Kargi, and A. Işikdemir, “The effect of CAPE on lipid peroxidation and nitric oxide levels in the plasma of rats following thermal injury,” Burns, vol. 30, no. 2, pp. 121–125, 2004. View at: Publisher Site | Google Scholar
  50. V. Silva, G. Genta, M. N. Möller et al., “Antioxidant activity of Uruguayan propolis. In vitro and cellular assays,” Journal of Agricultural and Food Chemistry, vol. 59, no. 12, pp. 6430–6437, 2011. View at: Publisher Site | Google Scholar
  51. J. Q. Zhao, Y. F. Wen, M. Bhadauria et al., “Protective effects of propolis on inorganic mercury induced oxidative stress in mice,” Indian Journal of Experimental Biology, vol. 47, no. 4, pp. 264–269, 2009. View at: Google Scholar
  52. I. Jasprica, A. Mornar, Ž. Debeljak et al., “In vivo study of propolis supplementation effects on antioxidative status and red blood cells,” Journal of Ethnopharmacology, vol. 110, no. 3, pp. 548–554, 2007. View at: Publisher Site | Google Scholar
  53. A. Kart, Y. Cigremis, H. Ozen, and O. Dogan, “Caffeic acid phenethyl ester prevents ovary ischemia/reperfusion injury in rabbits,” Food and Chemical Toxicology, vol. 47, no. 8, pp. 1980–1984, 2009. View at: Publisher Site | Google Scholar
  54. I. O. Tekin, E. Y. Sipahi, M. Comert, S. Acikgoz, and G. Yurdakan, “Low-density lipoproteins oxidized after intestinal ischemia/reperfusion in rats,” Journal of Surgical Research, vol. 157, no. 1, pp. e47–e54, 2009. View at: Publisher Site | Google Scholar
  55. Y. Aliyazicioglu, S. Demir, I. Turan et al., “Preventive and protective effects of Turkish propolis on H2O2 induced DNA damage in foreskin fibroblast cell lines,” Acta Biologica Hungarica, vol. 62, no. 4, pp. 388–396, 2011. View at: Google Scholar
  56. D. Remirez, R. González, S. Rodriguez et al., “Protective effects of propolis extract on allyl alcohol-induced liver injury in mice,” Phytomedicine, vol. 4, no. 4, pp. 309–314, 1997. View at: Google Scholar
  57. R. Claus, R. Kinscherf, C. Gehrke et al., “Antiapoptotic effects of propolis extract and propol on human macrophages exposed to minimally modified low density lipoprotein,” Arzneimittel-Forschung, vol. 50, no. 4, pp. 373–379, 2000. View at: Google Scholar
  58. C. Pascual, R. Gonzalez, and R. G. Torricella, “Scavenging action of propolis extract against oxygen radicals,” Journal of Ethnopharmacology, vol. 41, no. 1-2, pp. 9–13, 1994. View at: Publisher Site | Google Scholar
  59. R. O. A. de Lima, A. P. Bazo, R. A. Said et al., “Modifying effect of propolis on dimethylhydrazine-induced DNA damage but not colonic aberrant crypt foci in rats,” Environmental and Molecular Mutagenesis, vol. 45, no. 1, pp. 8–16, 2005. View at: Publisher Site | Google Scholar
  60. M. I. Isla, M. I. N. Moreno, A. R. Sampietro, and M. A. Vattuone, “Antioxidant activity of Argentine propolis extracts,” Journal of Ethnopharmacology, vol. 76, no. 2, pp. 165–170, 2001. View at: Publisher Site | Google Scholar
  61. S. Scheller, T. Wilczok, S. Imielski, W. Krol, J. Gabrys, and J. Shani, “Free radical scavenging by ethanol extract of propolis,” International Journal of Radiation Biology, vol. 57, no. 3, pp. 461–465, 1990. View at: Google Scholar
  62. M. Y. Heo, S. J. Sohn, and W. W. Au, “Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate,” Mutation Research, vol. 488, no. 2, pp. 135–150, 2001. View at: Publisher Site | Google Scholar
  63. A. A. Righi, T. R. Alves, G. Negri, L. M. Marques, H. Breyer, and A. Salatino, “Brazilian red propolis: unreported substances, antioxidant and antimicrobial activities,” Journal of the Science of Food and Agriculture, vol. 91, no. 13, pp. 2363–2370, 2011. View at: Google Scholar
  64. C. O. Frozza, C. S. Garcia, G. Gambato et al., “Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis,” Food and Chemical Toxicology, vol. 52, pp. 137–142, 2013. View at: Publisher Site | Google Scholar
  65. H. Izuta, M. Shimazawa, K. Tsuruma, Y. Araki, S. Mishima, and H. Hara, “Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells,” BMC Complementary and Alternative Medicine, vol. 9, article 45, 2009. View at: Publisher Site | Google Scholar
  66. A. Russo, V. Cardile, F. Sanchez, N. Troncoso, A. Vanella, and J. A. Garbarino, “Chilean propolis: antioxidant activity and antiproliferative action in human tumor cell lines,” Life Sciences, vol. 76, no. 5, pp. 545–558, 2004. View at: Publisher Site | Google Scholar
  67. L. G. Korkina, “Phenylpropanoids as naturally occurring antioxidants: from plant defense to human health,” Cellular and Molecular Biology, vol. 53, no. 1, pp. 15–25, 2007. View at: Publisher Site | Google Scholar
  68. P. Libby, “Inflammatory mechanisms: the molecular basis of inflammation and disease,” Nutrition Reviews, vol. 65, no. 12, pp. S140–S146, 2007. View at: Google Scholar
  69. A. P. Q. Mello, I. T. da Silva, D. S. P. Abdalla, and N. R. T. Damasceno, “Electronegative low-density lipoprotein: origin and impact on health and disease,” Atherosclerosis, vol. 215, no. 2, pp. 257–265, 2011. View at: Publisher Site | Google Scholar
  70. P. Libby, “Inflammation in atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2045–2051, 2012. View at: Google Scholar
  71. G. D. Norata, P. Marchesi, S. Passamonti, A. Pirillo, F. Violi, and A. L. Catapano, “Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice,” Atherosclerosis, vol. 191, no. 2, pp. 265–271, 2007. View at: Publisher Site | Google Scholar
  72. D. Grassi, A. Aggio, L. Onori et al., “Tea, flavonoids, and nitric oxide-mediated vascular reactivity,” Journal of Nutrition, vol. 138, no. 8, pp. 1554S–1560S, 2008. View at: Google Scholar
  73. S. Gorinstein, H. Leontowicz, M. Leontowicz et al., “Influence of two cultivars of persimmon on atherosclerosis indices in rats fed cholesterol-containing diets: Investigation in vitro and in vivo,” Nutrition, vol. 27, no. 7-8, pp. 838–846, 2011. View at: Google Scholar
  74. Y. Li, M. Chen, H. Xuan, and F. Hu, “Effects of encapsulated propolis on blood glycemic control, lipid metabolism, and insulin resistance in type 2 diabetes mellitus rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 981896, 8 pages, 2012. View at: Publisher Site | Google Scholar
  75. H. U. Fuliang, H. R. Hepburn, H. Xuan, M. Chen, S. Daya, and S. E. Radloff, “Effects of propolis on blood glucose, blood lipid and free radicals in rats with diabetes mellitus,” Pharmacological Research, vol. 51, no. 2, pp. 147–152, 2005. View at: Publisher Site | Google Scholar
  76. J. B. Daleprane, V. da Silva Freitas, A. Pacheco et al., “Anti-atherogenic and anti-angiogenic activities of polyphenols from propolis,” Journal of Nutritional Biochemistry, vol. 23, no. 6, pp. 557–566, 2012. View at: Publisher Site | Google Scholar
  77. A. Iio, K. Ohguchi, H. Maruyama et al., “Ethanolic extracts of Brazilian red propolis increase ABCA1 expression and promote cholesterol efflux from THP-1 macrophages,” Phytomedicine, vol. 19, no. 5, pp. 383–388, 2012. View at: Publisher Site | Google Scholar
  78. Y. Yu, Y. Si, G. Song, T. Luo, J. Wang, and S. Qin, “Ethanolic extract of propolis promotes reverse cholesterol transport and the expression of ATP-binding cassette transporter A1 and G1 in mice,” Lipids, vol. 46, no. 9, pp. 805–811, 2011. View at: Publisher Site | Google Scholar
  79. T. G. Chen, J. J. Lee, K. H. Lin, C. H. Shen, D. S. Chou, and J. R. Sheu, “Antiplatelet activity of caffeic acid phenethyl ester is mediated through a cyclic GMP-dependent pathway in human platelets,” Chinese Journal of Physiology, vol. 50, no. 3, pp. 121–126, 2007. View at: Google Scholar
  80. N. Paulino, S. R. L. Abreu, Y. Uto et al., “Anti-inflammatory effects of a bioavailable compound, Artepillin C, in Brazilian propolis,” European Journal of Pharmacology, vol. 587, no. 1–3, pp. 296–301, 2008. View at: Publisher Site | Google Scholar
  81. Y. S. Song, C. Jin, K. J. Jung, and E. H. Park, “Estrogenic effects of ethanol and ether extracts of propolis,” Journal of Ethnopharmacology, vol. 82, no. 2-3, pp. 89–95, 2002. View at: Publisher Site | Google Scholar
  82. T. U. Roos, E. H. Heiss, A. V. Schwaiberger et al., “Caffeic acid phenethyl ester inhibits PDGF-induced proliferation of vascular smooth muscle cells via activation of p38 MAPK, HIF-1α, and heme oxygenase-1,” Journal of Natural Products, vol. 74, no. 3, pp. 352–356, 2011. View at: Publisher Site | Google Scholar
  83. M. F. Brizzi, L. Formato, and R. Bonamini, “The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases,” Italian Heart Journal, vol. 2, no. 2, pp. 81–92, 2001. View at: Google Scholar
  84. P. Carmeliet, “Angiogenesis in life, disease and medicine,” Nature, vol. 438, no. 7070, pp. 932–936, 2005. View at: Publisher Site | Google Scholar
  85. A. A. Ucuzian, A. A. Gassman, A. T. East, and H. P. Greisler, “Molecular mediators of angiogenesis,” Journal of Burn Care and Research, vol. 31, no. 1, pp. 158–175, 2010. View at: Publisher Site | Google Scholar
  86. M. Keshavarz, A. Mostafaie, K. Mansouri, Y. Shakiba, and H. R. M. Motlagh, “Inhibition of corneal neovascularization with propolis extract,” Archives of Medical Research, vol. 40, no. 1, pp. 59–61, 2009. View at: Publisher Site | Google Scholar
  87. M. R. Ahn, K. Kunimasa, T. Ohta et al., “Suppression of tumor-induced angiogenesis by Brazilian propolis: major component artepillin C inhibits in vitro tube formation and endothelial cell proliferation,” Cancer Letters, vol. 252, no. 2, pp. 235–243, 2007. View at: Publisher Site | Google Scholar
  88. H. J. Hwang, H. J. Park, H. J. Chung et al., “Inhibitory effects of caffeic acid phenethyl ester on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells,” Journal of Nutritional Biochemistry, vol. 17, no. 5, pp. 356–362, 2006. View at: Publisher Site | Google Scholar
  89. U. H. Jin, T. W. Chung, S. K. Kang et al., “Caffeic acid phenyl ester in propolis is a strong inhibitor of matrix metalloproteinase-9 and invasion inhibitor: isolation and identification,” Clinica Chimica Acta, vol. 362, no. 1-2, pp. 57–64, 2005. View at: Publisher Site | Google Scholar
  90. H. F. Liao, Y. Y. Chen, J. J. Liu et al., “Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis,” Journal of Agricultural and Food Chemistry, vol. 51, no. 27, pp. 7907–7912, 2003. View at: Publisher Site | Google Scholar
  91. H. Xuan, J. Zhao, J. Miao, Y. Li, Y. Chu, and F. Hu, “Effect of Brazilian propolis on human umbilical vein endothelial cell apoptosis,” Food and Chemical Toxicology, vol. 49, no. 1, pp. 78–85, 2011. View at: Publisher Site | Google Scholar
  92. J. B. Daleprane, T. Schmid, N. Dehne et al., “Suppression of hypoxia-inducible factor-1α contributes to the antiangiogenic activity of red propolis polyphenols in human endothelial cells,” Journal of Nutrition, vol. 142, no. 3, pp. 441–447, 2012. View at: Google Scholar
  93. H. K. Eltzschig and T. Eckle, “Ischemia and reperfusion—from mechanism to translation,” Nature Medicine, vol. 17, no. 11, pp. 1391–1401, 2011. View at: Google Scholar
  94. H. Hattori, K. Okuda, T. Murase et al., “Isolation, identification, and biological evaluation of HIF-1-modulating compounds from Brazilian green propolis,” Bioorganic and Medicinal Chemistry, vol. 19, no. 18, pp. 5392–5401, 2011. View at: Google Scholar
  95. S. Umthong, S. Puthong, and C. Chanchao, “Trigona laeviceps propolis from Thailand: antimicrobial, antiproliferative and cytotoxic activities,” American Journal of Chinese Medicine, vol. 37, no. 5, pp. 855–865, 2009. View at: Publisher Site | Google Scholar
  96. E. Szliszka and W. Krol, “The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention,” European Journal of Cancer Prevention, vol. 20, no. 1, pp. 63–69, 2011. View at: Publisher Site | Google Scholar

Copyright © 2013 Julio Beltrame Daleprane and Dulcinéia Saes Abdalla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

7066 Views | 2641 Downloads | 36 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder
 Sign up for content alertsSign up